Travere Therapeutics (TVTX) Amortization of Deferred Charges (2014 - 2022)

Travere Therapeutics (TVTX) has 9 years of Amortization of Deferred Charges data on file, last reported at $428000.0 in Q4 2022.

• Quarterly Amortization of Deferred Charges fell 85.17% year-over-year to $428000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.6 million (down 73.28% YoY) and the FY2025 annual result came in at $1.6 million, down 4.93% from the prior year.
• Amortization of Deferred Charges steadied at $428000.0 in Q4 2022, from $428000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $9.2 million in Q4 2020 to a low of $50000.0 in Q3 2018.
• A 5-year average of $1.8 million and a median of $428000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2021 — Amortization of Deferred Charges soared 429.4% — and 2022, when it plunged 87.65%.
• Tracing TVTX's Amortization of Deferred Charges over 5 years: stood at $2.3 million in 2018, then soared by 284.1% to $8.8 million in 2019, then increased by 4.84% to $9.2 million in 2020, then sank by 68.61% to $2.9 million in 2021, then plunged by 85.17% to $428000.0 in 2022.
• The last three Amortization of Deferred Charges figures came in at $428000.0 (Q4 2022), $428000.0 (Q3 2022), and $429000.0 (Q2 2022), per Business Quant data.